Wayne Markowitz - 14 Sep 2023 Form 4 Insider Report for Edwards Lifesciences Corp (EW)

Role
GM & SVP, Surgical
Signature
Linda J. Park, Attorney-in-Fact
Issuer symbol
EW
Transactions as of
14 Sep 2023
Net transactions value
$0
Form type
4
Filing time
15 Sep 2023, 17:01:15 UTC
Previous filing
25 Aug 2023
Next filing
09 May 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EW Common Stock Award $0 +7,262 $0.000000 7,262 14 Sep 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EW Employee Stock Option (Right to Acquire) Award $0 +19,256 $0.000000 19,256 14 Sep 2023 Common Stock 19,256 $74.02 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These restricted stock units were granted on September 14, 2023 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested annually in equal installments over a period of four years commencing one year after the grant date.
F2 These options were granted on September 14, 2023 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable annually in equal installments over a period of four years commencing one year after the grant date.

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.